A multi-center randomized clinical trial published in JAMA Internal Medicine demonstrates that colchicine, despite its potent anti-inflammatory properties, fails to improve 6-minute walk test distances or inflammatory markers in patients suffering from Long COVID, highlighting the complexity of the condition's pathogenesis.